MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab
Authors:
Open Access
- 25 April 2024
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (8) , 2074-2083.e4
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca (GPP 2022)
This publication has 31 references indexed in Scilit:
- A Renewed Charter: Key Principles to Improve Patient Care in Severe AsthmaAdvances in Therapy, 2022
- In Reply—Are Eosinophils Needed for Normal Health?Mayo Clinic Proceedings, 2022
- Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 YearsThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Eosinophilic and Noneosinophilic AsthmaChest, 2021
- Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on BenralizumabDrug Safety, 2020
- Characterization of Severe Asthma WorldwideChest, 2020
- Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthmaJournal of Allergy and Clinical Immunology, 2019
- Reductions in eosinophil biomarkers by benralizumab in patients with asthmaRespiratory Medicine, 2016
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophiliaJournal of Allergy and Clinical Immunology, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012